NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

—To some extent, yes, say the results of a recent systematic review and meta-analysis. But were escalation therapies any more effective than platform therapies in boosting cognition? Share on Facebook ...

This publication was sponsored and written in partnership with Bristol-Myers Squibb. The American Journal of Managed Care ®: What are some specific patient characteristics associated with ...

MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...

The goal of this double-blind, adaptive, dose-ranging, phase 2 study was to assess safety, tolerability and dose-response characteristics of siponimod and its effects on brain MRI lesion activity in ...

I got married in 2014. I remember waking up with numb feet a couple months after we bought our house. But I didn’t think much of it at the time. I could always feel the floor again once I’d finished ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...